Mammoth Biosciences, one of the two companies developing CRISPR as a diagnostic tool, submitted a medRxiv preprint showcasing their work on a Covid-19 assay. The SARS-CoV-2 DETECTR assay generate results in 30 minutes from from extracted patient sample RNA. The assay performs simultaneous reverse transcription […]
In Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection researchers at the Institute of Human Genetics in Austria demonstrate the use of cfDNA for cancer detection and monitoring. The group performed deep ATAC-Seq and deep cfDNA nucleosome mapping to […]
#CRISPR diagnostics got even more exciting with two big announcements last month. Firstly, Sherlock Biosciences, has spun out from The Broad Institute and Wyss Institute commercialising the SHERLOCK and INSPECTR technologies (I’ll be covering the battle for CRISPR Dx dominance in this post). Secondly, researchers at […]
On Friday last week I had the pleasure of hosting a half-day Nanostring symposium at Cancer Research UK’s Cambridge Institute (my previous employer). The symposium was arranged as an opportunity to get Nanostring users, and potential users, together to hear about the exciting developments in […]
The FDA issued a safety communication today on the risk that biotin supplements “can significantly interfere with certain lab tests and cause incorrect test results”. The FDA communiqué mentions an increase in reported adverse events, and even one death, because of Biotin interference. Biotin interferes with some […]
Two papers in Science last week show how CRISPR can be used as a diagnostic tool. The first comes from the same team at The Broad that brought us the SHERLOCK method, the second from Jennifer Dounda’s group at Berkley. Both methods promise simple diagnostics […]
